Skip to main content

Advertisement

SpringerLink
Log in

Phosphodiesterase 11 A (PDE11A), a potential biomarker for glioblastoma

  • Original Article
  • Published:
Toxicological Research Aims and scope Submit manuscript

Abstract

Phosphodiesterase 11A (PDE11A), a 3′,5′-cyclic nucleotide phosphodiesterase, is a key regulator of intracellular signaling that functions by degrading cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). However, the function of PDE11A in brain tumors is currently unclear. In this study, we found that PDE11A may be involved in glioblastoma development. The protein and mRNA levels of PDE11A were significantly higher in U87-MG, U251-MG and U343-MG glioblastoma cell lines. Gene expression analyses by deep-sequencing revealed that PDE11A mRNA levels were higher in U87-MG and U251-MG cells compared to other cells in the cerebral cortex. A comprehensive analysis of The Cancer Genome Atlas (TCGA) data revealed that PDE11A expression was also elevated in glioblastoma patients. Taken together, these data indicate that PDE11A expression was increased in glioblastoma cell lines and glioma patients, suggesting that PDE11A could be a putative diagnostic marker and therapeutic target for glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1

    Article  PubMed  Google Scholar 

  2. Glaser T et al (2017) Targeted nanotechnology in glioblastoma multiforme. Front Pharmacol. https://doi.org/10.3389/fphar.2017.00166

    Article  PubMed  PubMed Central  Google Scholar 

  3. Virk SM et al (2015) Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing. PLoS One. https://doi.org/10.1371/journal.pone.0124178

    Article  PubMed  PubMed Central  Google Scholar 

  4. Singh SK et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. https://doi.org/10.1038/nature03128

    Article  CAS  PubMed  Google Scholar 

  5. Singh SK et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828. (PMID: 14522905)

    CAS  PubMed  Google Scholar 

  6. Brennan CW et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477. https://doi.org/10.1016/j.cell.2013.09.034

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kelly MP (2015) Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target? Curr Pharm Des 21:389–416. https://doi.org/10.2174/1381612820666140826114941

    Article  CAS  PubMed  Google Scholar 

  8. Hannah-Shmouni F, Faucz FR, Stratakis CA (2016) Alterations of phosphodiesterases in adrenocortical tumors. Front Endocrinol. https://doi.org/10.3389/fendo.2016.00111

    Article  Google Scholar 

  9. Conti M et al (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493–5496. https://doi.org/10.1074/jbc.R200029200

    Article  CAS  PubMed  Google Scholar 

  10. Giembycz MA (2002) Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 57:48–64. (PMID: 12174704)

    CAS  PubMed  Google Scholar 

  11. Ahmed WS, Geethakumari AM, Biswas KH (2021) Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors. Biomed Pharmacother 134:111128. https://doi.org/10.1016/j.biopha.2020.111128

    Article  CAS  PubMed  Google Scholar 

  12. Kim HB, Yoo BS (2016) Propolis inhibits UVA-induced apoptosis of human keratinocyte HaCaT cells by scavenging ROS. Toxicol Res 32:345–351. https://doi.org/10.5487/TR.2016.32.4.345

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Li Y et al (2013) PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage. Cell Signal 25:74–84. https://doi.org/10.1016/j.cellsig.2012.09.009

    Article  CAS  PubMed  Google Scholar 

  14. Na CH et al (2015) Identification of protein markers specific for papillary renal cell carcinoma using imaging mass spectrometry. Mol Cells 38:624–629. https://doi.org/10.14348/molcells.2015.0013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Demeure K et al (2016) Targeted proteomics to assess the response to anti-angiogenic treatment in human glioblastoma (GBM). Mol Cell Proteomics 15:481–492. https://doi.org/10.1074/mcp.M115.052423

    Article  CAS  PubMed  Google Scholar 

  16. Kim JE, Lim M (2015) The role of checkpoints in the treatment of GBM. J Neurooncol 123:413–423. https://doi.org/10.1007/s11060-015-1747-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hathout L, Patel V (2016) Estimating subthreshold tumor on MRI using a 3D-DTI growth model for GBM: an adjunct to radiation therapy planning. Oncol Rep 36:696–704. https://doi.org/10.3892/or.2016.4878

    Article  PubMed  Google Scholar 

  18. Carney JA et al (2010) Familial micronodular adrenocortical disease, Cushing syndrome, and mutations of the gene encoding phosphodiesterase 11A4 (PDE11A). Am J Surg Pathol 34:547–555. https://doi.org/10.1097/PAS.0b013e3181d31f49

    Article  PubMed  PubMed Central  Google Scholar 

  19. Koch L (2011) Cancer: PDE11a-a phenotype modifier in carney complex. Nat Rev Endocrinol 7:64. https://doi.org/10.1038/nrendo.2010.225

    Article  PubMed  Google Scholar 

  20. Faucz FR et al (2011) Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. J Clin Endocrinol Metab 96:E135–E140. https://doi.org/10.1210/jc.2010-1655

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was financially supported by a research fund from Chungnam National University (grant to SH Kim) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2021R1A2C1008492, NRF-2020R1F1A1049801, NRF-2021R1C1C200845611). The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/cNOwdf.

Funding

This study was funded by Chungnam National University (grant to SH Kim) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2021R1A2C1008492, NRF-2020R1F1A1049801, NRF-2021R1C1C200845611).

Author information

Author notes

  1. Hyunji Lee and Sungjin Park contributed equally to this work.

Authors and Affiliations

  1. Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, 35015, South Korea

    Hyunji Lee, Sungjin Park, Gyeyeong Kong, Jisoo Park & Jongsun Park

  2. Department of Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, 35015, South Korea

    Hyunji Lee, Sungjin Park, Gyeyeong Kong, Jisoo Park & Jongsun Park

  3. College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, 21983, South Korea

    So Hee Kwon

  4. Department of Life Science, Hyehwa Liberal Arts College, Daejeon University, Daejeon, 34520, South Korea

    Jisoo Park

  5. Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, 35015, South Korea

    Seon-Hwan Kim

Authors
  1. Hyunji Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sungjin Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gyeyeong Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. So Hee Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jisoo Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jongsun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Seon-Hwan Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by HL, SP and GK. The first drafty of the manuscripts was written by HL and SP and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Jongsun Park or Seon-Hwan Kim.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, H., Park, S., Kong, G. et al. Phosphodiesterase 11 A (PDE11A), a potential biomarker for glioblastoma. Toxicol Res. 38, 409–415 (2022). https://doi.org/10.1007/s43188-022-00129-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43188-022-00129-1

Keywords

Search

Navigation